The clinical trials of PARP inhibitors in ovarian cancer have yielded several key findings: The SOLO-1 trial showed that olaparib significantly extended progression-free survival (PFS) and overall survival (OS) in patients with BRCA mutations, with results consistent across Chinese and global populations (10). This evidence concerns the gene PARP1 and ovarian carcinoma.